Streptomyces 23-2B is one of actinomycetes associated with marine clam Donax trunculus and has potential source of bioactive metabolites, which possesses a broad spectrum antibiotic and anticancer activities. This study aims to evaluate the effect of Streptomyces 23-2B metabolites on hepatic lipid peroxidation (LPO), reduced glutathione (GSH) levels, as well as serum uric acid, total cholesterol (TC), triglyceride (TG), nitric oxide (NO) and tumor necrosis factor-alpha (TNF-α) levels of rat. Animals were divided into four groups: the control group, which received 0.1 ml of 10% Tween-80 by intraperitoneally injection, and the other three experimental groups, which received 10% Tween 80 solution of Streptomyces 23-2B metabolites in doses of 0.5, 5 and 50 mg/kg body weight at an interval 2 days for 2 weeks. LPO levels showed significant decrease with the lowest doses. The effect at a dose of 50 mg/kg of Streptomyces 23-2B metabolites on TG was more pronounced than the other two doses (0.5 and 5 mg/kg body weight). Hypocholesterolemia was recorded in the treated rats with 0.5 and 5 mg/kg of Streptomyces 23-2B. However, the highest dose enhanced the elevation of serum TNF-α and NO levels. Thus, the present study reveals that Streptomyces 23-2B metabolite is a newly discovered biomaterial from microorganisms. The novel substance showed inhibitory activity against LPO in rat liver homogenate and improving the immune response by releasing TNF-α and NO in serum.
Read full abstract